SCHEMBL7665205

SCHEMBL7665205

CC(C)(C)OC(=O)CNS(=O)(=O)c1ccc(OC(=O)c2ccc(C(=N)N)cc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 9/20 0.58
TMPRSS6 Q8IU80 6/20 0.58
PRSS1 P07477 4/20 0.42
TMPRSS15 P98073 2/20 0.42
FTO Q9C0B1 1/20 0.41
KDM4E B2RXH2 1/20 0.41
NPC1 O15118 1/20 0.41
ALDH1A1 P00352 1/20 0.41
GAA P10253 1/20 0.41
HPGD P15428 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
KLK1 P06870 2/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40
PKM P14618 1/20 0.40
PLG P00747 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7669520 1.00 F2 (0.58) F2TMPRSS6PRSS1TMPRSS15FTO
SCHEMBL7676248 0.90 F2 (0.57) F2TMPRSS6PRSS1ALDH1A1SMN1; SMN2
SCHEMBL7671933 0.89 F2 (0.56) F2TMPRSS6
Acetic Acid SCHEMBL7663094 0.87 TMPRSS6 (0.55) F2TMPRSS6PRSS1TMPRSS15KLK1
Acetic Acid SCHEMBL7667840 0.87 TMPRSS6 (0.55) F2TMPRSS6PRSS1TMPRSS15KLK1
SCHEMBL7675632 0.86 SMN1; SMN2 (0.51) F2TMPRSS6TMPRSS15KDM4ENPC1
SCHEMBL7673733 0.86 MAPT (0.49) F2TMPRSS6KDM4ENPC1ALDH1A1
SCHEMBL7670445 0.84 TMPRSS6 (0.51) F2TMPRSS6PRSS1TMPRSS15GAA
SCHEMBL7670690 0.84 TMPRSS6 (0.51) F2TMPRSS6PRSS1TMPRSS15GAA
SCHEMBL7669728 0.82 PLAU (0.45) F2TMPRSS6PRSS1TMPRSS15KLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6403644-B1 FOR PREVENTION AND/OR TREATMENT OF DISEASES INDUCED BY OVEREXPRESSION AND EXCESS ACTIVITY OF MATRIX METALLOPROTEINASE; FOR EXAMPLE, RHEUMATOID, ARTHROSTEITIS, UNUSUAL BONE RESORPTION, OSTEOPOROSIS, PERIODONTITIS ONO PHARMACEUTICAL CO., LTD. (JP) 2002-06-11 US disclosed
US-6177466-B1 Sulfonylamino acid derivatives ONO PHARMACEUTICAL CO., LTD. (JP) 2001-01-23 US disclosed
EP-0757037-A2 Sulfonylamino acid derivatives as metalloproteinase inhibitors ONO PHARMACEUTICAL CO., LTD. (JP) 1997-02-05 EP disclosed